Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;3(4):177-184.
doi: 10.1016/j.ajur.2016.08.003. Epub 2016 Aug 20.

Role of androgen receptor splice variants in prostate cancer metastasis

Jin Xu  1 , Yun Qiu  1
Affiliations

Role of androgen receptor splice variants in prostate cancer metastasis

Jin Xu et al. Asian J Urol. 2016 Oct.

Abstract

Prostate cancer (PCa) is one of the most lethal cancers in western countries. Androgen receptor (AR) signaling pathway plays a key role in PCa progression. Despite the initial effectiveness of androgen deprivation therapy (ADT) for treatment of patients with advanced PCa, most of them will develop resistance to ADT and progress to metastatic castration resistant prostate cancer (mCRPC). Constitutively transcriptional activated AR splice variants (AR-Vs) have emerged as critical players in the development and progression of mCRPC. Among AR-Vs identified to date, AR-V7 (a.k.a. AR3) is one of the most abundant and frequently found in both PCa cell lines and in human prostate tissues. Most of functional studies have been focused on AR-V7/AR3 and revealed its role in regulation of survival, growth, differentiation and migration in prostate cells. In this review, we will summarize our current understanding of regulation of expression and activity of AR-Vs in mCRPC.

Keywords: Androgen receptor; Metastatic castration; Prostate cancer; cancer; resistant prostate; splicing variants.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Proposed model of the role of AR-V7/AR3 in mCRPC. Upon androgen ablation, changes of genetic stability, transcription/splicing and epigenetic regulation alter the expression and activity of AR-V7. In addition to canonical AR–FL regulated genes, AR-V7 is able to regulate a subset distinct target genes to promote metastasis, cell survival and growth, and metabolic alteration in prostate cancer cells mCRPC: metastatic castration resistant prostate cancer.
See this image and copyright information in PMC

References

    1. American Cancer Society. Cancer facts & figures 2015. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2....
    1. George D., Moul J. Emerging treatment options for patients with castration resistant prostate cancer. Prostate. 2012;72:338–349. - PubMed
    1. Gelmann E. Molecular biology of the androgen receptor. J Clin Oncol. 2002;20:3001–3015. - PubMed
    1. Heinlein C., Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276–308. - PubMed
    1. Feldman B., Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1:34–45. - PubMed

LinkOut - more resources